Cover Image

Lexapro(重度憂鬱症)- 預測與市場分析

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 305474
出版日期 內容資訊 英文 45 Pages
Back to Top
Lexapro(重度憂鬱症)- 預測與市場分析 Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023
出版日期: 2014年05月30日 內容資訊: 英文 45 Pages



重度憂鬱症(MDD)是世界最常見的精神疾病之一。MDD市場競爭激烈,有30個以上的上市產品可用於患者的治療上。憂鬱症市場上,在主力產品(Eli Lilly的Cymbalta、大塚製薬/BMS的Abilify)專利即將到期,抗憂鬱症藥品的新產品(Lundbeck/武田薬品工業的Brintellix)及未來有望的後期階段開發平台產品即將上市的當下,市場正在大大變化中。


第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀和亞型
  • 預後
  • QOL

第4章 疾病的管理

  • 診斷和治療概要

第5章 競爭評估

  • 概要

第6章 Lexapro(Escitalopram)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄


Product Code: GDHC415DFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Lexapro (escitalopram) is an SSRI that was developed by Lundbeck; it initially gained marketing approval for MDD in 2002 in the US. Lexapro is the S-enantiomer of citalopram, an SSRI that was also developed by Lundbeck, which first became available in 1989. Lexapro acts by binding with high affinity to serotonin (5-HT), thereby inhibiting serotonin reuptake; this results in the higher levels of serotonin that are believed to exert antidepressant effects.


  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Lexapro including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Lexapro for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Lexapro performance
  • Obtain sales forecast for Lexapro from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms and Subtypes of Major Depressive Disorder
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Lexapro (Escitalopram)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5 Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed MDD Patients
    • 7.4.2. Percent of Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Analyst
    • 7.6.2. Therapy Area Directors
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013
  • Table 6: Leading Treatments for MDD, 2013
  • Table 7: Product Profile - Lexapro
  • Table 8: Safety of Lexapro - Five Most Frequently Reported Adverse Events
  • Table 9: Lexapro SWOT Analysis, 2014
  • Table 10: Global MDD Sales Forecasts ($m) for Lexapro, 2013-2023
  • Table 11: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
Back to Top